Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease

Neurobiology of Aging

Volumn 36, Issue 12, 2015, Pages 3306-3313

  Oeda, Tomoko ^a   Umemura, Atsushi ^a   Mori, Yuko ^a   Tomita, Satoshi ^a   Kohsaka, Masayuki ^a   Park, Kwiyoung ^a   Inoue, Kimiko ^b   Fujimura, Harutoshi ^b   Hasegawa, Hiroshi ^c   Sugiyama, Hiroshi ^a   Sawada, Hideyuki ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c National Hospital Organization Minami Kyoto Hospital   (Japan)

Author keywords

Clinical course; Glucocerebrosidase gene; MIBG scintigraphy; Parkinson's disease; Risk factor; SPECT

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUCOSYLCERAMIDASE; LEVODOPA; SELEGILINE;

AGED; ARTICLE; BRAIN BLOOD FLOW; CATECHOLAMINERGIC SYSTEM; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DSM-IV; FEMALE; GAUCHER DISEASE; GBA GENE; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MINI MENTAL STATE EXAMINATION; MYOCARDIAL PERFUSION IMAGING; PARIETAL CORTEX; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; SYMPATHETIC NERVE; BLOOD FLOW; COMPLICATION; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; MOTOR DISORDERS; MUTATION; PARIETAL LOBE; PATHOPHYSIOLOGY; RISK FACTOR; VASCULARIZATION;

AGED; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MOTOR DISORDERS; MUTATION; PARIETAL LOBE; PARKINSON DISEASE; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84947026903     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.08.027     Document Type: Article

References (46)

1. Alcalay R.N., Levy O.A., Waters C.C., Fahn S., Ford B., Kuo S.H., Mazzoni P., Pauciulo M.W., Nichols W.C., Gan-Or Z., Rouleau G.A., Chung W.K., Wolf P., Oliva P., Keutzer J., Marder K., Zhang X. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015, 138(Pt 9):2648-2658.
2. Anheim M., Elbaz A., Lesage S., Durr A., Condroyer C., Viallet F., Pollak P., Bonaiti B., Bonaiti-Pellie C., Brice A. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012, 78:417-420.
3. Bartenstein P., Minoshima S., Hirsch C., Buch K., Willoch F., Mosch D., Schad D., Schwaiger M., Kurz A. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J. Nucl. Med. 1997, 38:1095-1101.
4. Beavan M., McNeill A., Proukakis C., Hughes D.A., Mehta A., Schapira A.H. Evolution of Prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 2015, 72:201-208.
5. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., Martini C., Gioulis M., Pittis M.G., Capus L. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003, 61:99-101.
6. Brockmann K., Srulijes K., Hauser A.K., Schulte C., Csoti I., Gasser T., Berg D. GBA-associated PD presents with nonmotor characteristics. Neurology 2011, 77:276-280.
7. Brockmann K., Srulijes K., Pflederer S., Hauser A.K., Schulte C., Maetzler W., Gasser T., Berg D. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 2015, 30:407-411.
8. Chahine L.M., Qiang J., Ashbridge E., Minger J., Yearout D., Horn S., Colcher A., Hurtig H.I., Lee V.M., Van Deerlin V.M., Leverenz J.B., Siderowf A.D., Trojanowski J.Q., Zabetian C.P., Chen-Plotkin A. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013, 70:852-858.
9. Chiasserini D., Paciotti S., Eusebi P., Persichetti E., Tasegian A., Kurzawa-Akanbi M., Chinnery P.F., Morris C.M., Calabresi P., Parnetti L., Beccari T. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 2015, 10:15.
10. Clark L.N., Ross B.M., Wang Y., Mejia-Santana H., Harris J., Louis E.D., Cote L.J., Andrews H., Fahn S., Waters C., Ford B., Frucht S., Ottman R., Marder K. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007, 69:1270-1277.
11. Fishbein I., Kuo Y.M., Giasson B.I., Nussbaum R.L. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 2014, 137(Pt 12):3235-3247.
12. Gan-Or Z., Giladi N., Rozovski U., Shifrin C., Rosner S., Gurevich T., Bar-Shira A., Orr-Urtreger A. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008, 70:2277-2283.
13. Gegg M.E., Burke D., Heales S.J., Cooper J.M., Hardy J., Wood N.W., Schapira A.H. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 2012, 72:455-463.
14. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:745-752.
15. Goker-Alpan O., Masdeu J.C., Kohn P.D., Ianni A., Lopez G., Groden C., Chapman M.C., Cropp B., Eisenberg D.P., Maniwang E.D., Davis J., Wiggs E., Sidransky E., Berman K.F. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 2012, 135(Pt 8):2440-2448.
16. Goker-Alpan O., Schiffmann R., LaMarca M.E., Nussbaum R.L., McInerney-Leo A., Sidransky E. Parkinsonism among Gaucher disease carriers. J. Med. Genet. 2004, 41:937-940.
17. Halperin A., Elstein D., Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis 2006, 36:426-428.
18. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
19. Hirsch C., Bartenstein P., Minoshima S., Mosch D., Willoch F., Buch K., Schad D., Schwaiger M., Kurz A. Reduction of regional cerebral blood flow and cognitive impairment in patients with Alzheimer's disease: evaluation of an observer-independent analytic approach. Dement. Geriatr. Cogn. Disord. 1997, 8:98-104.
20. Koprivica V., Stone D.L., Park J.K., Callahan M., Frisch A., Cohen I.J., Tayebi N., Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am. J. Hum. Genet. 2000, 66:1777-1786.
21. Kresojevic N., Jankovic M., Petrovic I., Kumar K.R., Dragasevic N., Dobricic V., Novakovic I., Svetel M., Klein C., Pekmezovic T., Kostic V.S. Presenting symptoms of GBA-related Parkinson's disease. Parkinsonism Relat. Disord. 2015, 21:804-807.
22. Lesage S., Anheim M., Condroyer C., Pollak P., Durif F., Dupuits C., Viallet F., Lohmann E., Corvol J.C., Honore A., Rivaud S., Vidailhet M., Durr A., Brice A. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet. 2011, 20:202-210.
23. Li Y., Sekine T., Funayama M., Li L., Yoshino H., Nishioka K., Tomiyama H., Hattori N. Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol. Aging 2013, 35:935.e3-935.e8.
24. Lwin A., Orvisky E., Goker-Alpan O., LaMarca M.E., Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 2004, 81:70-73.
25. Machaczka M., Rucinska M., Skotnicki A.B., Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am. J. Hematol. 1999, 61:216-217.
26. Malec-Litwinowicz M., Rudzinska M., Szubiga M., Michalski M., Tomaszewski T., Szczudlik A. Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients. Neurol. Neurochir. Pol. 2014, 48:258-261.
27. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
28. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
29. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 1995, 36:1238-1248.
30. Mitsui J., Mizuta I., Toyoda A., Ashida R., Takahashi Y., Goto J., Fukuda Y., Date H., Iwata A., Yamamoto M., Hattori N., Murata M., Toda T., Tsuji S. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol. 2009, 66:571-576.
31. Murphy K.E., Gysbers A.M., Abbott S.K., Tayebi N., Kim W.S., Sidransky E., Cooper A., Garner B., Halliday G.M. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 2014, 137(Pt 3):834-848.
32. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996, 89:691-694.
33. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B., Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132(Pt 7):1783-1794.
34. Nichols W.C., Pankratz N., Marek D.K., Pauciulo M.W., Elsaesser V.E., Halter C.A., Rudolph A., Wojcieszek J., Pfeiffer R.F., Foroud T. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009, 72:310-316.
35. Noelker C., Lu L., Hollerhage M., Vulinovic F., Sturn A., Roscher R., Hoglinger G.U., Hirsch E.C., Oertel W.H., Alvarez-Fischer D., Andreas H. Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. J. Neurol. Sci. 2015, 356:129-136.
36. Sawada H., Oeda T., Yamamoto K., Kitagawa N., Mizuta E., Hosokawa R., Ohba M., Nishio R., Yamakawa K., Takeuchi H., Shimohama S., Takahashi R., Kawamura T. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur. J. Neurol. 2009, 16:174-182.
37. Schondorf D.C., Aureli M., McAllister F.E., Hindley C.J., Mayer F., Schmid B., Sardi S.P., Valsecchi M., Hoffmann S., Schwarz L.K., Hedrich U., Berg D., Shihabuddin L.S., Hu J., Pruszak J., Gygi S.P., Sonnino S., Gasser T., Deleidi M. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 2014, 5:4028.
38. Seto-Salvia N., Pagonabarraga J., Houlden H., Pascual-Sedano B., Dols-Icardo O., Tucci A., Paisan-Ruiz C., Campolongo A., Anton-Aguirre S., Martin I., Munoz L., Bufill E., Vilageliu L., Grinberg D., Cozar M., Blesa R., Lleo A., Hardy J., Kulisevsky J., Clarimon J. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 2012, 27:393-399.
39. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
40. Swan M., Saunders-Pullman R. The association between ss-glucocerebrosidase mutations and parkinsonism. Curr. Neurol. Neurosci. Rep. 2013, 13:368.
41. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., Fillano J.J., Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 2001, 73:313-321.
42. Tayebi N., Walker J., Stubblefield B., Orvisky E., LaMarca M.E., Wong K., Rosenbaum H., Schiffmann R., Bembi B., Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol. Genet. Metab. 2003, 79:104-109.
43. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
44. Uemura N., Koike M., Ansai S., Kinoshita M., Ishikawa-Fujiwara T., Matsui H., Naruse K., Sakamoto N., Uchiyama Y., Todo T., Takeda S., Yamakado H., Takahashi R. Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein. PLoS Genet. 2015, 11:e1005065.
45. Wang Y., Liu L., Xiong J., Zhang X., Chen Z., Yu L., Chen C., Huang J., Zhang Z., Mohmed A.A., Lin Z., Xiong N., Wang T. Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China. Behav. Brain Funct. 2012, 8:57.
46. Winder-Rhodes S.E., Evans J.R., Ban M., Mason S.L., Williams-Gray C.H., Foltynie T., Duran R., Mencacci N.E., Sawcer S.J., Barker R.A. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013, 136(Pt 2):392-399.